Last reviewed · How we verify
Ceftazidime-avibactam + Colistin/Polymyxin B
This combination uses ceftazidime-avibactam to inhibit bacterial cell wall synthesis while overcoming beta-lactamase resistance, paired with colistin/polymyxin B to disrupt bacterial cell membranes, providing synergistic activity against multidrug-resistant gram-negative bacteria.
This combination uses ceftazidime-avibactam to inhibit bacterial cell wall synthesis while overcoming beta-lactamase resistance, paired with colistin/polymyxin B to disrupt bacterial cell membranes, providing synergistic activity against multidrug-resistant gram-negative bacteria. Used for Multidrug-resistant gram-negative bacterial infections (including Pseudomonas aeruginosa and Acinetobacter baumannii), Hospital-acquired and ventilator-associated pneumonia, Complicated urinary tract infections.
At a glance
| Generic name | Ceftazidime-avibactam + Colistin/Polymyxin B |
|---|---|
| Sponsor | National University of Singapore |
| Drug class | Beta-lactam/beta-lactamase inhibitor + polymyxin antibiotic combination |
| Target | Bacterial peptidoglycan cross-linking enzymes (PBPs); beta-lactamases; bacterial cell membrane lipopolysaccharide and phospholipids |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftazidime is a third-generation cephalosporin that inhibits bacterial peptidoglycan cross-linking; avibactam is a beta-lactamase inhibitor that protects ceftazidime from enzymatic degradation. Colistin and polymyxin B are polymyxin antibiotics that bind to and disrupt bacterial lipopolysaccharide and phospholipid membranes. Together, this combination targets multidrug-resistant gram-negative pathogens including Pseudomonas aeruginosa and Acinetobacter baumannii through complementary mechanisms.
Approved indications
- Multidrug-resistant gram-negative bacterial infections (including Pseudomonas aeruginosa and Acinetobacter baumannii)
- Hospital-acquired and ventilator-associated pneumonia
- Complicated urinary tract infections
- Bloodstream infections
Common side effects
- Nephrotoxicity
- Neurotoxicity (polymyxin-related)
- Diarrhea
- Nausea
- Phlebitis at infusion site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: